Cervical Cancer Diagnostics Test Market 2023 by Key Players Analysis Hologic, Inc., Guided Therapeutics inc., Quest Diagnostics, Femasys, Zilico Limited

Cervical cancer diagnostic tests are used widely for detection of the precancerous or cancerous lesions in the cervix of a female. The cervical cancer diagnostics is the initial screening of the patients, done through Pap smear and HPV testing, in the next stage colposcopy and biopsy are used to further confirm the furthers. After the diagnosis performed successfully the patients then goes through imaging tests to start the grade of cancer.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/cervical-cancer-diagnostics-test-market/report-sample

Cervical cancer diagnostic test market is witnessing a considerable growth, attributed to the increasing prevalence of cervical cancer in women, worldwide. According to the World Health Organization (WHO), more than 270,000 women dies each year due to the cervical cancer; the cervical cancer mortality rate is higher in the developing countries due to improper detection at early stages of the disease. With the rising use of cervical cancer diagnostic tests for the early detection of the cervical cancer, the market is expected to grow at above average growth in coming years.

Some of the predominant driver of cervical cancer diagnostics test market includes weakened immune system of the women in developing countries due to lack of proper nutritional intake, increase infection of human papillomavirus (HPV), and over use of the oral contraceptive pills by the women. lifestyle related factor related factors such as smoking, and having more than one sex partner are also increases the chances of cervical cancer among women which interns driving the cervical cancer diagnostics tests market.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cervical-cancer-diagnostics-test-market

Over-diagnosis and over-treatment are some of the major hindrance to the growth of cervical cancer diagnostic market. Also the Pap screening test has very high false positive results and low sensitivity rate in the cervical cancer detection in recent years. Moreover speculation is also over the inability of HPV tests to distinguish between pre-cancer and self-limiting infection which interns limiting its popularity in recent years.

North America was the largest market for cervical cancer diagnostic test in 2014. The market dominance of North America is attributed to the high awareness of women towards the disease prevention in this region. Asia Pacific is the fasted growing market of cervical cancer diagnostic test attributed to the growing prevalence of the cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea and Australia.

Browse report at: https://www.psmarketresearch.com/market-analysis/cervical-cancer-diagnostics-test-market

Some of the major players operating in global cervical cancer diagnostics test market include, Abbott Laboratories, Hologic, Inc., Becton, Roche Diagnostics, Dickinson and Company, OncoHealth Corporation, Qiagen N.V., Guided Therapeutics, Inc., Quest Diagnostics, Femasys, Inc., and Zilico Ltd.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.